VANCOUVER, British Columbia, Feb. 23, 2005 (PRIMEZONE) -- Dr. John Todd, President and CEO of ProtoKinetix, Inc. (OTCBB:PKTX), is proud to announce that the first series of results showing the efficacy of chemically synthesized AFGP (antifreeze glycoprotein) has shown a very efficient cell preservation viability on a delicate human cell line (kidney cells). At concentration levels from 10 times to 100 times lower than reported with the natural compound, these new, non toxic, AFGP molecules showed cell viability preservation activity at temperatures ranging from +4 degrees C to -4 degrees C.
ProteoCell Biotechnologies laboratory in the Quebec Biotechnologies Innovation Centre reports that in attempting to determine the level of cryopreservation possible from this new synthetic AFGP, they found a greater than 300% increase in cell preservation at temperatures down to -20 degrees C.
About ProtoKinetix:
ProtoKinetix, Inc. is a scientific development company whose mission is the advancement of human health care. The Company's first entry into the commercial market place will be the launch of the first synthetically replicated antifreeze glycoprotein (AFGP). PKTX has developed a unique business model that brings together a vast pool of world recognized intellectual talent in a networked environment. This integrated scientific approach combines the disciplines of physics, chemistry and molecular biology in order to fast track product development.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.
On behalf of the Board of Directors, Dr. John Todd, President